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Presencia de células B con propiedades regulatorias en ganglios drenantes de un tumor 
murino. En cáncer, las células B han sido clásicamente asociadas a la presentación antigénica, 
secreción de anticuerpos y activación de células T. Recientemente se comenzó a investigar un posible rol negativo 
de los linfocitos B sobre la respuesta inmune antitumoral, debido a que se describieron ciertas subpoblaciones 
B con capacidad de afectar negativamente la respuesta inmune en enfermedades autoinmunes. El tumor muri-
no MCC es altamente inmunogénico en estadios tempranos; a medida que crece pierde su inmunogenicidad e 
induce inmunosupresión sistémica y tolerancia. En este modelo hemos demostrado previamente que el creci-
miento tumoral induce un marcado y progresivo aumento en el número y proporción de células B en los ganglios 
drenantes del tumor (TDLN) y un aumento menos marcado de células T regulatorias. El objetivo fue estudiar las 
características y función de las células B en los ganglios que drenan el tumor MCC y analizar si éstas podrían 
inhibir la respuesta contra el tumor favoreciendo su progresión. Encontramos que las células B en los TDLN 
presentan expresión aumentada de las moléculas CD86 y MHCII indicando su activación, y expresión intracelular 
de IL-10, FASL y Granzima B, moléculas con función inmunosupresora. Además, mostraron alta actividad inhibi-
toria de la proliferación T ex vivo y moderada secreción de anticuerpos. Los resultados indican que aun cuando 
persisten marcadores de activación de la respuesta inmune, las células B presentes en los ganglios drenantes 
del tumor muestran fenotipo regulatorio y actividad inhibitoria, sugiriendo que las mismas contribuirían al estado 
de tolerancia inmunológica característico del estadio de tumor avanzado.
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Resumen
In cancer, B cells have been classically associated with antibody secretion, antigen presentation 
and T cell activation. However, a possible role for B lymphocytes in impairing antitumor response 
and collaborating with tumor growth has been brought into focus. Recent reports have described the capacity 
of B cells to negatively affect immune responses in autoimmune diseases. The highly immunogenic mouse 
tumor MCC loses its immunogenicity and induces systemic immune suppression and tolerance as it grows. We 
have previously demonstrated that MCC growth induces a distinct and progressive increase in B cell number 
and proportion in the tumor draining lymph nodes (TDLN), as well as a less prominent increase in T regulatory 
cells. The aim of this research was to study B cell characteristics and function in the lymph node draining MCC 
tumor and to analyze whether these cells may be playing a role in suppressing antitumor response and favoring 
tumor progression. Results indicate that B cells from TDLN expressed increased CD86 and MHCII co-stimulatory 
molecules indicating activated phenotype, as well as intracellular IL-10, FASL and Granzyme B, molecules with 
regulatory immunosuppressive properties. Additionally, B cells showed high inhibitory upon T cell proliferation 
ex vivo, and a mild capacity to secrete antibodies. Our conclusion is that even when evidence of B cell-mediated  
activity of the immune response is present, B cells from TDLN exhibit regulatory phenotype and inhibitory activ-
ity, probably contributing to the state of immunological tolerance characteristic of the advanced tumor condition.  
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Abstract
The involvement of the host immune system in the 
control of cancer progression has been assessed for 
several years; nowadays, it is vastly accepted that anti-
tumor immunity occurs and that tumors have evolved an 
elaborate assembly of tricks to avoid immune- mediated 
rejection1. The mechanisms responsible of immune cell 
dysfunction in patients with cancer involve a wide diversity 
of soluble immunosuppressive factors (such as TGFβ, IL-10 
and the inhibitory ligands FasL and TRAIL) released by 
tumor cells or by various suppressor cells in the tumor 
microenvironment, including regulatory T cells (Tregs). 
In the last decades Tregs have been the major target 
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of efforts to therapeutically modulate their inhibitory 
activity in order to achieve tumor remission or prevent 
recurrences2, 3. More recent studies are currently fo-
cusing on the role of B cells in regulating the immune 
response. Although these cells have been classically 
associated with antibody secretion, antigen presenta-
tion and antitumor-T cell activation, a possible role for 
B lymphocytes in impairing antitumor response and 
collaborating with tumor growth has been brought into 
focus due to the recently described participation of a 
regulatory subset of B cells in autoimmune diseases4. 
The mouse sarcoma MCC is a highly immunogenic 
tumor widely used to study the effect of tumor development 
on the immune system5, 6. As MCC grows, its immunoge-
nicity declines and a state of tolerance against the tumor 
arises7, 8. We have recently demonstrated that MCC growth 
is accompanied by a marked and progressive increase in 
B cell number and proportion in the tumor draining lymph 
nodes (TDLN), along with a less prominent increase in 
Tregs7. While the participation of Tregs in the inhibition 
of the antitumor immune response has been broadly 
assessed9 the role of B cells is still a matter of debate. 
The aim of this paper was to study the characteristics 
of the B cell population present in the tumor draining 
lymph nodes, and to analyze whether these cells may 
play a role in favoring the establishment of tolerance and 
tumor progression.  
As we previously showed7, MCC growth increased B 
cell number at the TDLN during the immunogenic phase, 
with a peak at day 15 after tumor inoculum (Fig. 1a). We 
therefore obtained cells from TDLN of tumor bearing mice 
(TBM) on day 15 and analyzed B cell phenotype and 
function. As control, non tumor bearing mice (non- TBM) 
B cells were obtained from inguinal and axillary LN. We 
found that B cells from TBM exhibited activated phenotype 
characterized by increased CD86 and MHCII expression 
Fig. 1.– Phenotype of B cells present in lymph nodes draining the tumor (TDLN). Lymph nodes from 
control and tumor bearing mice were aseptically disaggregated and 1x106 cells were incubated with 
fluorochrome-conjugated monoclonal antibodies. For intracellular staining cells were fixed and per-
meabilized prior to antibody staining. Cells were analyzed using a FACS flow cytometer and Winmdi 
software. One of three comparable experiments is shown (n = 3 to 4 mice per group, *p < 0.05, 
**p < 0.01, ***p < 0.001). A) B cell number increases as tumor grows. B cells were identified by anti-
B220 and counted by flow cytometry. A representative tumor growth curve is included. B-C) TDLN 
B cells exhibit predominantly regulatory phenotype. Surface expression of MHCI, MHCII, CD80 and 
CD86 (black for tumor bearing mice and grey for non tumor bearing mice) and FasL and intracellular 
expression of IL-10 and GZM B were assessed at day 15. 
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(Fig. 1b). Interestingly, these cells also expressed IL-10, 
FASL and Granzyme B (Fig. 1c), which were shown to 
induce immunosuppression in other systems10. On the 
other hand, B cells isolated from TBM showed inhibitory 
effect upon allogenically-induced T cell proliferation (Fig. 
2a), while no effect was observed on MCC cultures (data 
not shown). Finally, a moderate titer of specific anti- MCC 
antibodies was detected in the serum of TBM (Fig. 2b), 
indicating that B cells retain their ability as antibody 
secreting-cells.
Discussion 
Immune antitumor response emerges from the balance 
between regulatory and activated cells. It is now accepted 
that tumor presence leads to the appearance of regulatory 
immunosuppressive cell populations that not only affect 
endogenous antitumor response but also weaken the ef-
ficacy of immunotherapies. Regulatory T cells have been 
vastly assessed as one of the main inhibitory cell popula-
tion. However, multiple regulatory mechanisms have been 
proposed in the last years for B cells in different abnormal 
immune system conditions. Some of them need cell to cell 
contact to be effective (FasL and PDL2) while others are 
mediated by B cell- secreted soluble molecules, TGFβ, 
Granzyme B and IL-1010. 
Together with signs of immune activation, such as 
increased expression of the surface markers CD86 and 
MHCII and secretion of antibodies against MCC, B cells 
from lymph nodes draining the tumor seemed to be pre-
dominantly immunosuppressive, as suggested by the 
expression of IL-10, FasL and Granzyme B. Importantly, 
these cells were able to inhibit in vitro- induced T cell 
proliferation, which could indicate that the negative effect 
of B cells on tumor immunity is mostly indirect through 
affecting T cells. 
The presence of regulatory B cells was recently 
proposed to favor tumor progression in other models. 
Interleukin-10 secreted by B cells- was shown to reduce 
IFNγ secretion by cytotoxic CD8+ T cells11 and increase 
Treg cells presence12, thus impairing antitumor reaction. 
On the other hand, Granzyme B expressed by B cells 
infiltrating tumors had the capacity to negatively regulate 
T cell proliferation13.
Results presented herein indicate that along with some 
evidences of B cell- mediated activation of the immune 
response, the tumor also induces the emergence of a 
population of B cells with regulatory characteristics. We 
propose that these cells through different mechanisms 
such as IL-10, Granzyme B and FasL expression, could 
impede a proper antitumor response and collaborate with 
the immunological tolerance detected in advanced tumor 
bearing hosts.
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Fig. 2.– Function of B cells present in TDLN. A) B cells from tumor bearing mice suppress T cell pro-
liferation. Mitomycin C –treated AKR mouse spleen cells (2x105) were cultured with Balb/c LN cells 
(2x105) to generate an allogeneic stimulus for 96 h, with a final 18 h pulse of 1 μCi/well [3H]-thymidine. 
Incorporated radioactivity was measured in a liquid scintillation Beta counter. Mitomycin C- treated B 
cells (75x103) isolated from Balb/c control or tumor bearing mice were added from the beginning of the 
culture. One of two reproducible experiments is shown (n = 3 mice per group, p < 0.001). B) Tumor- 
reactive antibodies are present in sera from tumor bearing mice. Binding of sera IgG to tumor cells 
was evaluated by indirect ELISA, after incubating sera and MCC cells with anti-mouse IgG coupled 
to HRP and TMB as substrate (one of two experiments done n = 6 - 7, p < 0.05).
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LA TAPA
G. Guidi. Hemofagocitosis. Grabado basado en el diseño de Guidi.
Ilustración tomada de Guido Banti (1852-1925) Anatomia Patologica. Volume primo. Parte II. Capitolo 
ottavo. Infezione tifiche (p116-30), p 122. Milano: Società Editrice Libraria, 1907.
La leyenda dice: “Fig. 42. Bazo en la fiebre tifoidea: a residuo de un folículo, con pocos linfocitos 
y algunas células epitelioides; b porción de pulpa remanente infiltrada de glóbulos rojos; c macrófago 
con linfocitos en variados períodos de destrucción; d macrófago conteniendo glóbulos rojo, con núcleo 
normal; y e y h macrófagos necróticos, sin núcleo reconocible, conteniendo glóbulos rojos hinchados; 
f masa homogénea proveniente de la fusión de células necróticas; g fragmentos de células necróticas 
(ocular 3, objetivo 8, KoritsKa)”. En el texto: “En la pulpa se ven numerosos macrófagos, similares en 
aspecto a aquellos descriptos en el intestino y glándulas linfáticas las cuales fagocitan y destruyen con 
mucha actividad linfocitos y glóbulos rojos”.
Los macrófagos que fagocitan células sanguíneas (hemofagocitosis) se llamaron células de Rin-
dfleisch, por Georg Eduard von Ridfleisch (1836-1908) que las denominó “células tíficas”; se encuentran 
en el tejido linfoide del intestino, ganglios linfáticos y bazo. Las discusiones acerca de su origen fueron 
violentas. Para William George MacCallum (1874-1944) las describieron, y notaron su capacidad fa-
gocítica, Friedrich Albin Hoffmann (1843-1924) y Christian Albert Theodor Billroth (1829-1894). Frank 
Burr Mallory (1862-1941) decidió que eran células endoteliales. Felix Jacob Marchand (1846-1928) que 
derivaban de las células reticulares y endoteliales, y Sergius Saltikow (¿18xx?-19xx?) que eran células 
endoteliales de senos linfáticos mezcladas con células linfoides de varios tipos. 
MacCallum dice que no son peculiares de la fiebre tifoidea e idénticas a las observadas en la tuber-
culosis y otras afecciones y prefiere considerarlas macrófagos, miembros de la familia de las células 
migrantes mononucleares. El tiempo dio la razón a MacCallum quien no menciona a Rindfleisch. (Mac-
Callum WG. A Textbook of pathology. Philadelphia: Saunders, 1926, 4th. Ed. Chapter XXI, Typhoid 
infections, p560-577). Ver también: Fisman DN. Hemophagocytic Syndromes and Infection. Emerging 
Infec Dis 2000; 6: 601-8; Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consump-
tive anemia of inflammation. J Exp Med 2011; 208:1203-14; Usmani GN, Woda BA, Newburger PE. 
Advances in understanding the pathogenesis of HLA [Haemophagocytic Lymphohistiocytosis] Br J Hae-
matol 2013; 16: 609-22.
